|
1
|
Holtkamp GM, Kijlstra A, Peek R and de Vos
AF: Retinal pigment epithelium-immune system interactions: Cytokine
production and cytokine-induced changes. Prog Retin Eye Res.
20:29–48. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Momma Y, Nagineni CN, Chin MS, Srinivasan
K, Detrick B and Hooks JJ: Differential expression of chemokines by
human retinal pigment epithelial cells infected with
cytomegalovirus. Invest Ophthalmol Vis Sci. 44:2026–2033. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Elner SG, Delmonte D, Bian ZM, Lukacs NW
and Elner VM: Differential expression of retinal pigment epithelium
(RPE) IP-10 and interleukin-8. Exp Eye Res. 83:374–379. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dick AD: Doyne lecture 2016: Intraocular
health and the many faces of inflammation. Eye (Lond). 31:87–96.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sugita S, Kawazoe Y, Imai A, Yamada Y,
Horie S and Mochizuki M: Inhibition of Th17 differentiation by
anti-TNF-alpha therapy in uveitis patients with Behcet's disease.
Arthritis Res Ther. 14:R992012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Okada AA, Goto H, Ohno S and Mochizuki M;
Ocular Behçet's Disease Research Group Of Japan, : Multicenter
study of infliximab for refractory uveoretinitis in Behcet disease.
Arch Ophthalmol. 130:592–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takeuchi M, Kezuka T, Sugita S, Keino H,
Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, et
al: Evaluation of the long-term efficacy and safety of infliximab
treatment for uveitis in Behcet's disease: A multicenter study.
Ophthalmology. 121:1877–1884. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jaffe GJ, Dick AD, Brezin AP, Nguyen QD,
Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus
A, Scales D, et al: Adalimumab in patients with active
noninfectious uveitis. N Engl J Med. 375:932–943. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brenner D, Blaser H and Mak TW: Regulation
of tumour necrosis factor signalling: Live or let die. Nat Rev
Immunol. 15:362–374. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayden MS and Ghosh S: NF-kB in
immunobiology. Cell Res. 21:223–244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okamoto H, Cujec TP, Yamanaka H and
Kamatani N: Molecular aspects of rheumatoid arthritis: Role of
transcription factors. FEBS J. 275:4463–4470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kawai T and Akira S: Signaling to
NF-kappaB by Toll-like receptors. Trends Mol Med. 13:460–469. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu J, Ding J, Yang J, Guo X and Zheng Y:
MicroRNA roles in the nuclear factor kappa B signaling pathway in
cancer. Front Immunol. 9:5462018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ariga A, Namekawa J, Matsumoto N, Inoue J
and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced
nuclear translocation and activation of NF-kappa B by
dehydroxymethylepoxyquinomicin. J Biol Chem. 277:24625–24630. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Umezawa K: Inhibition of tumor growth by
NF-kappaB inhibitors. Cancer Sci. 97:990–995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Umezawa K and Chaicharoenpong C: Molecular
design and biological activities of NF-kappaB inhibitors. Mol
Cells. 14:163–167. 2002.PubMed/NCBI
|
|
17
|
Yamamoto M, Horie R, Takeiri M, Kozawa I
and Umezawa K: Inactivation of NF-kappaB components by covalent
binding of (−)-dehydroxymethylepoxyquinomicin to specific cysteine
residues. J Med Chem. 51:5780–5788. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin Y, Ukaji T, Koide N and Umezawa K:
Inhibition of late and early phases of cancer metastasis by the
NF-kB inhibitor DHMEQ derived from microbial bioactive metabolite
epoxyquinomicin: A review. Int J Mol Sci. 19:E7292018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Juel HB, Faber C, Udsen MS, Folkersen L
and Nissen MH: Chemokine expression in retinal pigment epithelial
ARPE-19 cells in response to coculture with activated T cells.
Invest Ophthalmol Vis Sci. 53:8472–8480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zanon Cde F, Sonehara NM, Girol AP, Gil CD
and Oliani SM: Protective effects of the galectin-1 protein on in
vivo and in vitro models of ocular inflammation. Mol Vis.
21:1036–1050. 2015.PubMed/NCBI
|
|
21
|
Yang PM, Wu ZZ, Zhang YQ and Wung BS:
Lycopen inhibits ICAM-1 expression and NF-kB activation by
Nrf2-regulated cell redox state in human retinal pigment epithelial
cells. Life Sci. 155:94–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mestdagh P, Van Vlierberghe P, De Weer A,
Muth D, Westermann F, Speleman F and Vandesompele J: A novel and
universal method for microRNA RT-qPCR data normalization. Genome
Biol. 10:R642009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen YH, Chen CL, Liang CM, Liang JB, Tai
MC, Chang YH, Lu DW and Chen JT: Silibinin inhibits ICAM-1
expression via regulation of N-linked and O-linked glycosylation in
ARPE-19 cells. Biomed Res Int. 2014:7013952014.PubMed/NCBI
|
|
25
|
Elner VM, Burnstine MA, Strieter RM,
Kunkel SL and Elner SG: Cell-associated human retinal pigment
epithelium interleukin-8 and monocyte chemotactic protein-1:
Immunochemical and in-situ hybridization analyses. Exp Eye Res.
65:781–789. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagai N, Izumi-Nagai K, Oike Y, Koto T,
Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K and
Ishida S: Suppression of diabetes-induced retinal inflammation by
blocking the angiotensin II type 1 receptor or its downstream
nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci.
48:4342–4350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen JT, Liang JB, Chou CL, Chien MW, Shyu
RC, Chou PI and Lu DW: Glucosamine sulfate inhibits TNF-alpha and
IFN-gamma-induced production of ICAM-1 in human retinal pigment
epithelial cells in vitro. Invest Ophthalmol Vis Sci. 47:664–672.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen JT, Chen PL, Chang YH, Chien MW, Chen
YH and Lu DW: Glucosamine sulfate inhibits leukocyte adhesion in
response to cytokine stimulation of retinal pigment epithelial
cells in vitro. Exp Eye Res. 83:1052–1062. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Whitcup SM, Chan CC, Li Q and Nussenblatt
RB: Expression of cell adhesion molecules in posterior uveitis.
Arch Ophthalmol. 110:662–666. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Whitcup SM, DeBarge LR, Caspi RR, Harning
R, Nussenblatt RB and Chan CC: Monoclonal antibodies against ICAM-1
(CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune
uveitis. Clin Immunol Immunopathol. 67:143–150. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Uchio E, Kijima M, Tanaka S and Ohno S:
Suppression of experimental uveitis with monoclonal antibodies to
ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci. 35:2626–2631.
1994.PubMed/NCBI
|
|
32
|
Crane IJ, McKillop-Smith S, Wallace CA,
Lamont GR and Forrester JV: Expression of the chemokines
MIP-1alpha, MCP-1, and RANTES in experimental autoimmune uveitis.
Invest Ophthalmol Vis Sci. 42:1547–1552. 2001.PubMed/NCBI
|
|
33
|
Foxman EF, Zhang M, Hurst SD, Muchamuel T,
Shen D, Wawrousek EF, Chan CC and Gery I: Inflammatory mediators in
uveitis: Differential induction of cytokines and chemokines in Th1-
versus Th2-mediated ocular inflammation. J Immunol. 168:2483–2492.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Keino H, Takeuchi M, Kezuka T, Yamakawa N,
Tsukahara R and Usui M: Chemokine and chemokine receptor expression
during experimental autoimmune uveoretinitis in mice. Graefes Arch
Clin Exp Ophthalmol. 241:111–115. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wakamatsu K, Nanki T, Miyasaka N, Umezawa
K and Kubota T: Effect of a small molecule inhibitor of nuclear
factor-kappaB nuclear translocation in a murine model of arthritis
and cultured human synovial cells. Arthritis Res Ther.
7:R1348–R1359. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iwata D, Kitaichi N, Miyazaki A, Iwabuchi
K, Yoshida K, Namba K, Ozaki M, Ohno S, Umezawa K, Yamashita K, et
al: Amelioration of experimental autoimmune uveoretinitis with
nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin
in mice. Invest Ophthalmol Vis Sci. 51:2077–2084. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ando Y, Keino H, Kudo A, Hirakata A, Okada
AA and Umezawa K: Anti-inflammatory effect of
dehydroxymethylepoxyquinomicin, a nuclear factor-kB inhibitor, on
endotoxin-induced uveitis in rats in vivo and in vitro. Ocul
Immunol Inflamm. 28:240–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gaudio PA: A review of evidence guiding
the use of corticosteroids in the treatment of intraocular
inflammation. Ocul Immunol Inflamm. 12:169–192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Van Bogaert T, De Bosscher K and Libert C:
Crosstalk between TNF and glucocorticoid receptor signaling
pathways. Cytokine Growth Factor Rev. 21:275–286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ukaji T and Umezawa K: Novel approaches to
target NF-kB and other signaling pathways in cancer stem cells. Adv
Biol Regul. 56:108–115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
de Castro Barbosa ML, da Conceicao RA,
Fraga AGM, Camarinha BD, de Carvalho Silva GC, Lima AGF, Cardoso EA
and de Oliveira Freitas Lione V: NF-kB signaling pathway inhibitors
as anticancer drug candidates. Anticancer Agents Med Chem.
17:483–490. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Miyake A, Dewan MZ, Ishida T, Watanabe M,
Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T and Horie R:
Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes
by the NF-kappaB inhibitor DHMEQ. Microbes Infect. 10:748–756.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fukushima T, Kawaguchi M, Yorita K, Tanaka
H, Takeshima H, Umezawa K and Kataoka H: Antitumor effect of
dehydroxymethylepoxyquinomicin, a small molecule inhibitor of
nuclear factor-kB, on glioblastoma. Neuro Oncol. 14:19–28. 2012.
View Article : Google Scholar : PubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBI
|
